GLP-1 use before hip replacement beats bariatric surgery on 90-day revision risk

The wire

1. 01In a propensity-matched retrospective cohort published in HSS Journal, patients on a GLP-1 receptor agonist within 18 months before primary THA had lower 90-day risks of revision, periprosthetic joint infection, ED visits, readmission, wound dehiscence and dislocation than patients with recent bariatric surgery.
2. 02Lower PJI, readmission and all-cause revision risk persisted to one year, which bears on how surgeons approach preoperative weight optimization.
3. 03This is Level III retrospective database evidence drawn from TriNetX coding; it cannot establish causation and residual confounding between the two weight-loss pathways remains.

From the source

GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study

HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026 Oct 7 · Brahmbhatt S, Mathew A, Shoap S et al.